Secoisolariciresinol

CAS No. 29388-59-8

Secoisolariciresinol( —— )

Catalog No. M24214 CAS No. 29388-59-8

Secoisolariciresinol is an enterolignan precursor, it has antioxidant, and estrogen-like activities, it can significantly suppress triglyceride (TG) accumulation in 3T3-L1 adipocytes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 288 In Stock
10MG 428 In Stock
25MG 701 In Stock
50MG 981 In Stock
100MG 1323 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Secoisolariciresinol
  • Note
    Research use only, not for human use.
  • Brief Description
    Secoisolariciresinol is an enterolignan precursor, it has antioxidant, and estrogen-like activities, it can significantly suppress triglyceride (TG) accumulation in 3T3-L1 adipocytes.
  • Description
    Secoisolariciresinol is an enterolignan precursor, it has antioxidant, and estrogen-like activities, it can significantly suppress triglyceride (TG) accumulation in 3T3-L1 adipocytes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF-α
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    29388-59-8
  • Formula Weight
    362.4
  • Molecular Formula
    C20H26O6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    COC1=C(C=CC(=C1)C[C@@H](CO)[C@@H](CC2=CC(=C(C=C2)O)OC)CO)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.The Effect of Secoisolariciresinol on 3T3-L1 Adipocytes and the Relationship between Molecular Structure and Activity.Biosci Biotechnol Biochem. 2009 Jan;73(1):35-9.
molnova catalog
related products
  • Homovanillyl alcohol

    Homovanillyl alcohol is a biological metabolite of Hydroxytyrosol.?

  • XYLOBIOSE

    XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.

  • Thalidomide

    Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.